Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Antibodies in Drug Discovery

Antibodies in Drug Discovery

Keynote Speakers

Paul Insel
Vice-Chair and Distinguished Professor, Pharmacology, University of California San Diego

Christian Klein
Expert Scientist/Head, Roche Pharmaceutical Research & Early Development, Roche Innovation Center Zurich

John McCafferty
Founder & CEO, IONTAS Ltd


SELECTBIO is pleased to announce Antibodies in Drug Discovery 2016, which will be held on 9 - 10 February 2016 in Cambridge, UK. The event is part of our Cambridge Workshop Series.

Attracting researchers, academics and industry professionals working in antibody research, this event will fully explore the latest developments in the design and engineering of antibodies in relation to the burgeoning field of biotherapeutics. Topics to be addressed include, engineering challenges and techniques, new technologies and business hurdles when developing antibodies, the latest developments in autoimmune and infectious disease research.

As a result of a major shift in focus of many pharmaceutical companies from small molecules to a portfolio that contains protein and chemical therapeutic agents, rapid progress has been made in the area of antibodies for drug discovery.

If you work in antibody drug discovery research you will benefit from the expert knowledge of academic and industry leaders who are pushing the boundaries of antibody discovery, whilst networking with the technology providers who are enabling them to do so.

Agenda Topics

  • Antibody Drug Conjugates (ADCs)
  • CAR/CAR-T Cells
  • Humanised Single Domain Antibodies for Research and Therapeutic Applications
  • Novel Immune Check Point Therapeutics, PD1 and Beyond
  • Patented Antibodies and Related Technologies in Europe
  • Targeting Ion Channels with Biologics

Sponsorship and Exhibition Opportunities

Exhibition Team,
+44 (0) 1206 501654

Distinguished Faculty

Robert Williams, Chief Drug Development Scientist, Cancer Research UK
Mahendra Deonarain, Chief Science & Operating Officer, Antikor Biopharma Ltd
Trevor Hallam, Chief Scientific Officer, Sutro Biopharma Inc
Roger Beerli, CSO, NBE Therapeutics
Martin Pule, Director Chimeric Antigen Receptor (CAR) Programme. Founder & Chief Scientific Officer, UCL Autolus
John Castle, Executive Director, Vaccine Research and Translational Medicine, Agenus Switzerland Inc.
Stefan Dubel, Full Professor and Director, Technische Universit├Ąt Braunschweig
Franck Perez, Group Leader, Institut Curie
Stefan Weigand, Head of Large Molecule Research, F. Hoffmann-La Roche Ltd
Patrick Chames, Main Scientist, INSERM
Roman Kischel, Principal Scientist, Amgen Research
Lioudmila Tchistiakova, Senior Director, Pfizer Inc
John Li, Senior Scientist, MedImmune
Tristan Vaughan, Vice President, R&D, Antibody Discovery and Protein Engineering, MedImmune Ltd

Corporate SponsorsWeb SponsorsOffical Journal PartnerNetworking
Drug Discovery WorldU-Networks